Work

An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC)

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.3632

Authors: Y. Humblet, M. Peeters, H. Bleiberg, R. Stupp, C. Sessa, A. Roth, J. Nippgen, A. Nolting, P. Stuart, G. Giaccone

Institutions: Merck KGaA, Darmstadt (Germany), Ghent University Hospital, Institut Jules Bordet, Centre Hospitalier Universitaire Vaudois, Istituto Oncologico della Svizzera Italiana, Amsterdam UMC Location Vrije Universiteit Amsterdam

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2245844780

Cites:

Cited by: 4

Related to: 10